Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

Who gets to sue the FDA? Is pharma caught in a trade war? And what does “AF” stand for?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Sarah Owermohle joins us to explain the Supreme Court case that could have dramatic effects on access to medication abortion — and the development of new medicines. We also discuss the latest news in the life sciences, including a contrarian take on a new obesity treatment, a congressional effort to ban Chinese biotech companies, and how we managed to make 300 episodes of this podcast.

For more on what we cover, here’s the latest on the mifepristone case; here’s where you can find Adam’s newsletter; here’s more on WuXi and Congress; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].